Wir sind mit live! Mehr erfahren

Enveric Biosciences

ENVB

Börsenwert 6,18 Mio. $

1,38 USD

-0,01

0,72 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

1 Tag

-0,72 %

5 Tage

-3,5 %

1 Monat

-7,38 %

3 Monate

1,47 %

6 Monate

-41,28 %

Seit Jahresbeginn

-62,4 %

1 Jahr

-85,41 %

5 Jahre

-99,99 %

10 Jahre

-100 %

Profil: Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.

Mitarbeiter: 6

Gesundheitswesen Biotechnologie

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 16,7 %

Neutral 83,3 %

Negativ 0 %

Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application covering novel compounds within its EVM401 Series of drug candidates. The EVM401 Series comprises proprietary, non-hallu.

Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that Joseph Tucker, Ph.D., CEO of Enveric will deliver a virtual presentation at the H.C. Wainwright 28th Annual Global Investment Conference, which is being held September 14-16, 2026, in New York City. In the prerecorded presentation, Dr. Tucker.

Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2026, and provided a comprehensive business update. CEO Commentary: "The second quarter was highlighted by important progress across the key activities supporting our planned first-in-human clin.

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026

Enveric Biosciences Says New Preclinical Data Confirms Non-Hallucinogenic Profile For Lead Psychiatric Candidate

Biotechnology firm Enveric Biosciences (NASDAQ:ENVB) revealed additional preclinical findings reinforcing the non-hallucinogenic nature of its primary drug candidate, EB-003.

Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced new preclinical data that further supports the growing body of evidence reinforcing the non-hallucinogenic profile of its lead candidate, EB-003. Preclinical testing of EB-003 was conducted using a targeted, highly sensitive GloSensor™ cAMP assay,.

Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today welcomed the U.S. Food and Drug Administration's (FDA) recent release of finalized guidance for clinical investigations of psychedelic and psychedelic-inspired therapeutics. “The final guidance reflects the FDA's continued engagement with clinical developme.

Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development

Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced its participation in the B. Riley Securities Mind, Muscle & Vision Summit, being held on July 16, 2026, in Boston, MA. Joseph Tucker, Ph.D., CEO of Enveric, will participate in a Neuropsychiatry Fireside Chat to discuss current trends within t.

Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit

Enveric Biosciences Announces Participation in 2026 BIO International Convention

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the company is participating in the BIO International Convention being held June 22-25, 2026, in San Diego, California. “We are arriving at BIO with strong operational momentum, driven by the recently announced positive preclinical phototoxic.

Enveric Biosciences Announces Participation in 2026 BIO International Convention

Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the company is participating in the UBS 3rd Virtual CNS Day being held on June 15, 2026. During the virtual event, members of Enveric's management team will conduct one-on-one meetings with registered investors to discuss the company's busine.

Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day

Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced the Initiation of Investigational New Drug (IND)-enabling Genotoxicity studies of its lead candidate neuroplastogen, EB-003. The initiated Good Laboratory Practice (GLP) studies will evaluate the potential for the compound to interact with DNA and.

Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt